QI
LXRX icon

QS Investors’s Lexicon Pharmaceuticals LXRX Stock Holding History

QS Investors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-436
Closed -$6K – 2019
2016
Q4 		$6K Hold
436
– – ﹤0.01% 1457
2016
Q3 		$8K Hold
436
– – ﹤0.01% 1435
2016
Q2 		$6K Hold
436
– – ﹤0.01% 1467
2016
Q1 		$5K Sell
436
-98,564
-100% -$1.03M ﹤0.01% 1471
2015
Q4 		$1.32M Buy
+99,000
New +$1.22M 0.01% 743

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QS Investors's LXRX Position: Q1 2017 in Review

QS Investors sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2017, closing a stake of 436 shares — an estimated $6K sold.

QS Investors first reported a position in LXRX in Q4 2015 and held it in 5 quarters. The position peaked at $1.32M in Q4 2015. 137 funds tracked by Wall St. Rank hold LXRX as of Q1 2017.

  • QS Investors reported no remaining Lexicon Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • QS Investors sold 436 Lexicon Pharmaceuticals shares in Q1 2017, an estimated $6K.
  • QS Investors first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 5 quarters.
  • QS Investors's Lexicon Pharmaceuticals position peaked at $1.32M in Q4 2015.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2017.

Based on QS Investors's 13F filing for Q1 2017, filed 15 May 2017.